Sandoz Reveals Biosimilar Denosumab Program
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
You may also be interested in...
Samsung Bioepis has announced that its Prolia/Xgeva (denosumab) biosimilar, SB16, has begun Phase I clinical trials. Further, the company’s Lucentis (ranibizumab) biosimilar, SB11, has produced positive Phase III data and has been filed in the US. Meanwhile, CEO and president Christopher Hansung Ko has commented on the impact of the coronavirus pandemic on the industry and competition from domestic companies in the Chinese market.
Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.
Novartis has no plans to sell Sandoz, nor to move the generics division’s headquarters from its current location in Holzkirchen, Germany. Legacy German brand Hexal also remains part of the company’s plans.